[PDF][PDF] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

S Faivre, C Delbaldo, K Vera, C Robert… - Journal of clinical …, 2006 - Citeseer
S Faivre, C Delbaldo, K Vera, C Robert, S Lozahic, N Lassau, C Bello, S Deprimo, N Brega…
Journal of clinical oncology, 2006Citeseer
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine
Kinase Inhibitor, in Patients With Page 1 Safety, Pharmacokinetic, and Antitumor Activity of
SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Sandrine
Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau,
Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini, Jean-Pierre Armand, Paul
Scigalla, and Eric Raymond A B S T R A C T Purpose To establish the safety, pharmacokinetics …
Purpose
To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.
Citeseer